Human monoclonal antibodies (mAbs) were derived from lymph node lymphocytes and peripheral blood lymphocytes (PBL) from patients with melanoma. Four methods for generating human mAbs were compared: fusion with human [LICR-LON-HMy-2 (LICR-2)] or mouse (NS-1) cells; transformation by Epstein-Barr virus (EBV); and EBV transformation followed by NS-1 fusion. NS-1 fusion with lymph node lymphocytes resulted in a higher number of growing hybrids than LICR-2 fusion. Virtually no hybrids were obtained from NS-1 or LICR-2 fusions with PBL. EBV transformed lymphocytes from lymph node and peripheral blood with equal efficiency, and the yield of proliferating cultures for antibody screening was more than 10-to 30-fold greater than that obtained by fusion techniques. However, once antibodyproducing cultures had been identified, stability and clonability of EBV-transformed cells were poorer than that of NS-1 hybrid cells. To combine the strengths of both methods, cultures of EBV-transformed cells were fused with NS-1, and hybrid clones were isolated that showed vigorous growth, clonability, and stable antibody secretion. Detailed specificity analysis of the mAbs produced by six of these clones indicated detection of a class 1 (unique) melanoma antigen, a class 3 melanoma antigen, and four ganglioside antigens (GD3, GM3, and two other, as yet uncharacterized, heterophile antigens).
Several groups have reported specific humoral and cellular immune reactions to melanoma cell-surface antigens (1) (2) (3) (4) (5) (6) (7) (8) (9) . In our laboratory, the reactivity of serum with surface antigens of cultured melanoma cells from the same patient (termed autologous typing) has been analyzed in >200 patients. Three classes of antigens have been defined in this way (2) . Class 1 (unique) melanoma antigens are restricted to the autologous melanoma; six examples of class 1 antigens have been detected (10) (11) (12) (13) (14) (15) . Class 2 melanoma antigens are detected on the autologous melanoma, on a subset of allogeneic melanoma cells, and on other neuroectodermally derived tumors, and one of the best-analyzed class 2 melanoma antigens is the ganglioside GD2 (16) . Class 3 melanoma antigens are not restricted to any differentiation lineage and are more widely distributed.
The advent of methods for producing human monoclonal antibodies (mAbs) through immortalizing human lymphocytes with Epstein-Barr virus (EBV) (17) or by fusion with human or mouse lymphoblastoid/myeloma partners (18) provides a new level of precision in the analysis of the immune response to melanoma. Houghton et al. (19) , Irie and co-workers (20) (21) (22) , and other groups (23, 24) have isolated antibodies from melanoma patients reacting with melanoma cell surfaces or intracellular antigens. In the present study, we compared the efficiency of EBV immortalization and hybridization with mouse or human partners in the capture of human lymphocytes producing melanoma-reactive antibody. By combining the two techniques-i.e., EBV transformation followed by fusion with mouse NS-1 myeloma-we have been successful in generating a panel of human mAbs reactive with cell-surface antigens of melanoma.
MATERIALS AND METHODS
Tissue Culture. Tumor cell lines were established and maintained as described (10) . Several melanoma cell lines (see Table 1 ) were adapted to growth in serum-free insulin (5 ,ug/ml)/transferrin (5 ,ug/ml)/selenium (5 Ag/ml) (ITS) medium.
Fusion Procedure. Lymph node lymphocytes (LNL) and peripheral blood lymphocytes (PBL) were isolated by Ficoll/ Hypaque centrifugation and fused with human LICR-LONHMy-2 (LICR-2) lymphoblastoid cells or mouse NS-1 myeloma cells as described (19, 25 Serological Assays. Techniques for the detection of cellsurface antigens (11, 14) and intracellular antigens (19, 25) have been described. Antigen characterization by heat treatment and neuraminidase treatment was performed as described (27, 28 Glycolipids. Cells were extracted by chloroform/methanol, and neutral and acidic glycolipids were isolated as described (28) . GM3 and GD3 were purified in this laboratory. GM2 was prepared as described (29) . GM1, GD1a, and GT1 were purchased from Supelco (Bellefonte, PA). GD2 was a generous gift of H. Wiegandt (University Marburg, F.R.G.). GD1b was kindly given by R. K. Yu (Yale University, New Haven, CT).
ELISA for glycolipids and immunostaining after TLC were performed as described (28) (29) (30) . Immunology: Yamaguchi et al.
RESULTS
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Immunology: Yamaguchi et al. an acidic glycolipid. Antibody inhibition tests with purified gangliosides showed that HJM1 was strongly inhibited by GD3 and GD2, inhibited less by GD1b and GM3, and not inhibited by GM2, GM1, and GD1a (Fig. 2) . Immunostaining of TLC plates confirmed the strong reactivity of HJM1 with GD3 (Fig. 3) (Fig. 4) . Immunostaining of TLC plates confirmed this strong reactivity of FCM1 for GM3 and GD1a (Fig. 3) allogeneic melanoma cell line (titer, 1/40,000) but not for the autologous melanoma cell line. A comparison of the absorption analysis ofDSM1 and high-titered serum from patient DS showed identical results (data not shown), indicating that the mAb has the same specificity as serum antibody. EBVtransformed B cells from the donor of the SK-MEL-13 target cell (AH) did not absorb reactivity from DSM1 or DS serum, suggesting that alloantigenic systems such as HLA class 1 or class 2 antigens were not involved. The antigen detected by DSM1 is heat-labile, hydrophobic, and binds to Con A (H.Y. and P. Srivastava, unpublished observations). 32 origin and antigen expression, the reactivity of 32-27M disappeared when cells were cultured in serum-free ITS medium in the absence of fetal bovine serum (Table 2 ). When fetal bovine serum was returned to the medium, partial recovery of 32-27M reactivity occurred after 6 hr of incubation and full recovery of reactivity was observed after 24 hr of incubation. The antigen is heat-stable and neuraminidasesensitive, suggesting an acidic glycolipid. In immunostaining, 32-27M reacted with a number of acidic glycolipids in sheep erythrocyte extracts (Fig. 3 ). It appears that neuroectodermally derived cells, but not most other cell types, incorporate this antigen from fetal bovine serum.
2-39M. 2-39M is an IgM antibody derived from LNL of a melanoma patient. It does not react with any of the human cultured cell lines or human erythrocytes (Table 2) . It agglutinates sheep erythrocytes and reacted with an acidic glycolipid isolated from these cells in immunostaining (Fig.  3) .
DISCUSSION
EBV transformation and cell-fusion techniques represent distinct approaches to the isolation of human mAbs. Each method, as currently applied, combines certain advantages and certain limitations. For instance, easy clonability is an advantage with methods depending on hybrid formation (particularly NS-1 hybrids) that is not achievable with EBVtransformed cells at this time. However, there is a higher likelihood that antibody-secreting populations will be identified after EBV infection, because of the polyclonal proliferation of EBV-infected cells, than after the more stringent and inherently more random process of hybrid formation. By using these two approaches sequentially (31, 32) Several of the mAbs derived in this study identify antigens that exemplify the features of the three classes of antigens identified by autologous and allogeneic typing of human serum using conventional serological methods (2) . The antigen recognized by GXM1 has the characteristic of a class 1 (unique) melanoma antigen-i.e., highly restricted expression to autologous melanoma cells. The availability of a mAb to a human class 1 antigen should facilitate study of this class of antigen and determine whether they are a related family of antigens and whether homologous molecules are expressed by normal cells. The antigen detected by HJM1 has the characteristics of a class 2 melanoma antigen-i.e., expression by the autologous melanoma, and a subset of allogeneic melanomas, but not by cells of nonneuroectodermal origin. HJM1 reacts strongly with GD3 and reacts less with GD2, two gangliosides that are widely expressed by neuroectodermal cells. Because individuals can develop humoral antibody against these normally occurring cell-surface components, we have termed this class of tumor antigen autoimmunogenic differentiation antigens (16 immunoselection for low-expression variants in these patients or have these variants been fortuitously selected in vitro? Immunoselection of stable antigen-negative or lowexpressing tumor cell variants has been obtained in mice (33) and in humans (34) following passive administration of anti-ganglioside antibodies. It is not difficult to imagine that a similar process could occur as a consequence of an autologous humoral immune response.
